Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence…
- Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00923130).
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence…
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: Complete Statistical AnalysisIndependent statistical analysis of Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03167411).
- BFAKneeIndependent statistical analysis of Ear Acupuncture for Pain Associated With Ambulatory Arthroscopic Knee Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01447329).
- BFFIndependent statistical analysis of Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03496545).
- BFR Therapy in Patients With Rotator Cuff Tears: Complete Statistical AnalysisIndependent statistical analysis of BFR Therapy in Patients With Rotator Cuff Tears: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04384120).
- BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST): Complete Statistical AnalysisIndependent statistical analysis of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).: Complete Statistical AnalysisIndependent statistical analysis of BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI 10773 add-on to Metformin in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of BI 10773 add-on to Metformin in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 409306 in Patients With Cognitive Impairment Due to Alzheimer’s Disease.: Complete Statistical AnalysisIndependent statistical analysis of BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 425809 in Patients With Cognitive Impairment Due to Alzheimer’s Disease.: Complete Statistical AnalysisIndependent statistical analysis of BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…
- BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02123823).
- BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia: Complete Statistical AnalysisIndependent statistical analysis of BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BIANCAIndependent statistical analysis of Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Biatain Silicone Sacral for Pressure Injury Prevention in Hospital-admitted Patients at Risk: Complete Statistical AnalysisIndependent statistical analysis of Biatain Silicone Sacral for Pressure Injury Prevention in Hospital-admitted Patients at Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BiBIndependent statistical analysis of The Budesonide in Babies (BiB) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04545866).
- BiBETIndependent statistical analysis of Optimized Biventricular Pacing Allograft Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290822).
- BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery: Complete Statistical AnalysisIndependent statistical analysis of BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery: primary endpoint results, effect estimate with…
- BIBSIndependent statistical analysis of Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02188459).
- BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00708214).
- BICARBIndependent statistical analysis of Dietary Acid Load, Kidney Function and Disability in Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02691663).
- Bicarbonate for Tumor Related Pain: Complete Statistical AnalysisIndependent statistical analysis of Bicarbonate for Tumor Related Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01350583).
- BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05087524).
- BINDIndependent statistical analysis of Procedural Discomfort Related to Number of Intradetrusor Botox Injections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05652036).
- BingocizeIndependent statistical analysis of Bingocize: A Novel Mobile Application for Older Adult Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03629912).
- Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT): Complete Statistical AnalysisIndependent statistical analysis of Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326781).
- Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants: primary endpoint results, effect estimate with…
- Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir: Complete Statistical AnalysisIndependent statistical analysis of Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: Complete Statistical AnalysisIndependent statistical analysis of Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BioButton Among Nursing Home Residents: Complete Statistical AnalysisIndependent statistical analysis of BioButton Among Nursing Home Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06665685).
- Biochemotherapy With Temozolomide for Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Biochemotherapy With Temozolomide for Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00505635).
- BioCSI-2Independent statistical analysis of Biomarkers of Cockroach Sublingual Immunotherapy 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380327).
- Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions:…
- Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers: primary endpoint…
- Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions: primary…
- Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306): Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): primary endpoint results, effect estimate with confidence interval,…